Logo-jrip
ePublished: 24 Apr 2016
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2016;5(2): 79-84.
doi: 10.15171/jrip.2016.17
PMID: 27471739
PMCID: PMC4962674
  Abstract View: 3470
  PDF Download: 2048

Original Article

Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients

Leila Bagheri 1, Maryam Hami 1*, Mohammad-Javad Mojahedi 1, Mahin Ghorban Sabbagh 1, Hosein Ayatollahi 2

1 Kidney Transplantation Complications Research Center, Montaserieh Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Hematology and Blood Banking Department, Cancer Molecular Pathology Research Center, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
*Corresponding Author: *Corresponding author: Maryam Hami,, Email: hamim@mums.ac.ir

Abstract

Introduction: Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose and lipid homeostasis and insulin sensitivity.

Objectives: The aim of this study was to investigate the relation between the serum level of FGF21 with and metabolic syndrome (MS) in kidney transplant recipients.

Patients and Methods: We performed a cross-sectional study on 86 stable renal transplant
recipients to detect possible relation between serum FGF21 level and MS during October 2014
and Mach 2015. Patients with past history of diabetes mellitus were excluded.

Results: There were 43 patients in each group with and without MS. Totally, they were 52
(60.5%) male and 34 (39.5%) female. The mean age of the MS group was significantly higher
than that of non-MS group. There was not significant difference between mean serum
creatinine level and glomerular filtration rate (GFR) between two groups (P > 0.05). The MS
patients had higher weight and body mass index (BMI) (P < 0.05). The prevalence of BMI
>25 kg/m2 in MS group was 25 (58.8%) versus non-MS group that only 10 (23.3%) had this
condition (P < 0.05). The mean of FGF21 level in MS and non-MS groups was 1.23 ± 0.67 ng/l
and 1.18 ± 0.71 ng/l, respectively (P > 0.05). There was not significant difference of serum
FGF21 level between MS and non-MS patients (P > 0.05).

Conclusion: While the elevated serum FGF21 level was found in subjects with insulin resistant
states, however, this study revealed that serum FGF21 levels were not significantly increased
in renal transplanted recipients with MS as compared with non-MS group.

 

Implication for health policy/practice/research/medical education:

In a cross-sectional study on 86 stable renal transplant recipients to detect the association between serum fibroblast growth factor 21 (FGF21) level with metabolic syndrome (MS), we found serum FGF21 levels were not significantly raised in the renal transplant recipients with MS group when compared with non-MS group.

Please cite this paper as: Bagheri L, Hami M, Mojahedi MJ, Ghorban Sabbagh M, Ayatollahi H. Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients. J Renal Inj Prev. 2016;5(2):79-84. DOI: 10.15171/jrip.2016.17

 
 \
First Name
Last Name
Email Address
Comments
Security code


Abstract View: 3471

Your browser does not support the canvas element.


PDF Download: 2048

Your browser does not support the canvas element.